Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. / Haslund-Krog, Sissel Sundell; Schmidt, Maria; Mathot, Ron; Kryger Jensen, Andreas; Jørgensen, Inger Merete; Holst, Helle.

I: BMJ Paediatrics Open, Bind 3, Nr. 1, e000520, 2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Haslund-Krog, SS, Schmidt, M, Mathot, R, Kryger Jensen, A, Jørgensen, IM & Holst, H 2019, 'Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease', BMJ Paediatrics Open, bind 3, nr. 1, e000520. https://doi.org/10.1136/bmjpo-2019-000520

APA

Haslund-Krog, S. S., Schmidt, M., Mathot, R., Kryger Jensen, A., Jørgensen, I. M., & Holst, H. (2019). Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. BMJ Paediatrics Open, 3(1), [e000520]. https://doi.org/10.1136/bmjpo-2019-000520

Vancouver

Haslund-Krog SS, Schmidt M, Mathot R, Kryger Jensen A, Jørgensen IM, Holst H. Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. BMJ Paediatrics Open. 2019;3(1). e000520. https://doi.org/10.1136/bmjpo-2019-000520

Author

Haslund-Krog, Sissel Sundell ; Schmidt, Maria ; Mathot, Ron ; Kryger Jensen, Andreas ; Jørgensen, Inger Merete ; Holst, Helle. / Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. I: BMJ Paediatrics Open. 2019 ; Bind 3, Nr. 1.

Bibtex

@article{f63c12fb2dfa4326a4f7568ddef24ce1,
title = "Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease",
abstract = "Introduction One in three Danish children under 3 years of age experience asthma-like symptoms, and one-third will later be diagnosed with asthma. Oral prednisolone is used in various formulations to treat acute asthma. However, the potential differences in bioequivalence between these formulations have never been examined in children despite interchangeable use in clinical practice.Methods and analysis An open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease.The included patients (6 monthstextendash11 years of age) are admitted to the Department of Paediatric and Adolescent Medicine Nordsj{\ae}llands University Hospital, Hiller{\o}d, with asthma or asthma-like symptoms.The primary objective is to assess the bioequivalence between different prednisolone formulations herein area under the concentration time curve, Cmax and Tmax using saliva samples. The secondary objectives are to evaluate tolerability (five-point face scale), adverse events and severity of the disease. If the patient has an intravenous access for other purposes, the saliva samples will be validated with plasma samples.A total of 66 evaluable patients are needed according to European Medicines Agency Guideline on bioequivalence.Ethics and dissemination Traditional pharmacokinetic trials are burdensome due to the extent of blood samples necessary to capture the time-dependant drug profile. Saliva sampling is far more acceptable for paediatric patients. In addition, this trial adheres to standard dosing strategies. No additional venepunctures are performed, and no additional prednisolone doses are administered.Guidelines for paediatric bioequivalence trials are warranted.Trial registration number The Danish Medicines Agency EudraCT: 2017-003590-33, The Ethics Committee case no: H-17027252, and the Danish Data Protection Agency: BFH-2017textendash103, I-Suite no.: 05935.",
author = "Haslund-Krog, {Sissel Sundell} and Maria Schmidt and Ron Mathot and {Kryger Jensen}, Andreas and J{\o}rgensen, {Inger Merete} and Helle Holst",
year = "2019",
doi = "10.1136/bmjpo-2019-000520",
language = "Udefineret/Ukendt",
volume = "3",
journal = "BMJ Paediatrics Open",
issn = "2399-9772",
publisher = "BMJ Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease

AU - Haslund-Krog, Sissel Sundell

AU - Schmidt, Maria

AU - Mathot, Ron

AU - Kryger Jensen, Andreas

AU - Jørgensen, Inger Merete

AU - Holst, Helle

PY - 2019

Y1 - 2019

N2 - Introduction One in three Danish children under 3 years of age experience asthma-like symptoms, and one-third will later be diagnosed with asthma. Oral prednisolone is used in various formulations to treat acute asthma. However, the potential differences in bioequivalence between these formulations have never been examined in children despite interchangeable use in clinical practice.Methods and analysis An open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease.The included patients (6 monthstextendash11 years of age) are admitted to the Department of Paediatric and Adolescent Medicine Nordsjællands University Hospital, Hillerød, with asthma or asthma-like symptoms.The primary objective is to assess the bioequivalence between different prednisolone formulations herein area under the concentration time curve, Cmax and Tmax using saliva samples. The secondary objectives are to evaluate tolerability (five-point face scale), adverse events and severity of the disease. If the patient has an intravenous access for other purposes, the saliva samples will be validated with plasma samples.A total of 66 evaluable patients are needed according to European Medicines Agency Guideline on bioequivalence.Ethics and dissemination Traditional pharmacokinetic trials are burdensome due to the extent of blood samples necessary to capture the time-dependant drug profile. Saliva sampling is far more acceptable for paediatric patients. In addition, this trial adheres to standard dosing strategies. No additional venepunctures are performed, and no additional prednisolone doses are administered.Guidelines for paediatric bioequivalence trials are warranted.Trial registration number The Danish Medicines Agency EudraCT: 2017-003590-33, The Ethics Committee case no: H-17027252, and the Danish Data Protection Agency: BFH-2017textendash103, I-Suite no.: 05935.

AB - Introduction One in three Danish children under 3 years of age experience asthma-like symptoms, and one-third will later be diagnosed with asthma. Oral prednisolone is used in various formulations to treat acute asthma. However, the potential differences in bioequivalence between these formulations have never been examined in children despite interchangeable use in clinical practice.Methods and analysis An open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease.The included patients (6 monthstextendash11 years of age) are admitted to the Department of Paediatric and Adolescent Medicine Nordsjællands University Hospital, Hillerød, with asthma or asthma-like symptoms.The primary objective is to assess the bioequivalence between different prednisolone formulations herein area under the concentration time curve, Cmax and Tmax using saliva samples. The secondary objectives are to evaluate tolerability (five-point face scale), adverse events and severity of the disease. If the patient has an intravenous access for other purposes, the saliva samples will be validated with plasma samples.A total of 66 evaluable patients are needed according to European Medicines Agency Guideline on bioequivalence.Ethics and dissemination Traditional pharmacokinetic trials are burdensome due to the extent of blood samples necessary to capture the time-dependant drug profile. Saliva sampling is far more acceptable for paediatric patients. In addition, this trial adheres to standard dosing strategies. No additional venepunctures are performed, and no additional prednisolone doses are administered.Guidelines for paediatric bioequivalence trials are warranted.Trial registration number The Danish Medicines Agency EudraCT: 2017-003590-33, The Ethics Committee case no: H-17027252, and the Danish Data Protection Agency: BFH-2017textendash103, I-Suite no.: 05935.

U2 - 10.1136/bmjpo-2019-000520

DO - 10.1136/bmjpo-2019-000520

M3 - Tidsskriftartikel

C2 - 31646194

VL - 3

JO - BMJ Paediatrics Open

JF - BMJ Paediatrics Open

SN - 2399-9772

IS - 1

M1 - e000520

ER -

ID: 228216215